Background: There are limited data on the outcomes of pancreas transplants using ABO non-identical but compatible (NIC) donors.
| INTRODUC TI ON
Pancreas transplantation is an established treatment option for patients with type 1 diabetes mellitus (T1D) as well as select patients with type 2 diabetes mellitus. In the United States, 1.25 million people have T1D including about 200 000 youth (<20 years old) and over a million adults (>20 years old). 1 Despite the high prevalence of T1D and improving transplant outcomes, the number of pancreas transplants have declined over the last decade. [2] [3] [4] In the year 2016, only 1013 pancreas allografts were transplanted (798 simultaneous kidney and pancreas (SPK) and 215 isolated pancreas transplants), which is down from a peak of 1484 pancreas transplants in 2004.
This represents a 32% decrease.
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The ABO blood group is the most important of all the blood group systems. There are 4 different ABO blood groups (see Table 1 ), determined by whether or not an individual's cells carry the A antigen, the B antigen, both A and B antigens (AB) or neither (O).
Normal healthy individuals, from early in childhood, develop antibodies against A or B antigens that are not expressed on their own cells. Recipients may receive organs from donors with the same or compatible blood types, meaning to which they do not have preexisting antibodies. Additionally, there are also potentially compatible combinations that involve the donor blood type A2 and there are instances where incompatible transplants are acceptable, but this is beyond the scope of this report.
There are numerous studies describing utilization of ABO nonidentical but compatible (NIC) donors for heart 6, 7 and lung transplantation. 8, 9 Most of these studies have shown no statistically significant difference in long term graft survival among identical and NIC transplants. There are emerging studies regarding intestine transplantation that may suggest that NIC intestine/multi-visceral transplants may have higher rates of rejection. 10 
| MATERIAL S AND ME THODS
A retrospective analysis of medical record data at a single institu- A review of medical history revealed that 4 patients had hypothyroidism, 3 had rheumatoid arthritis and 2 were on anticoagulation for hyper-coagulable states in the study group. In the control group, 3 patients had hypothyroidism, 1 had Grave's disease and 2 were on anticoagulation for hyper-coagulable state and atrial fibrillation.
However, none had any past medical history of hemolytic diseases.
Donor organs were procured in a standard fashion as described previously. 16 The recipient operation was performed through a midline incision. The pancreas was routinely positioned with the tail toward the pelvis and the head and duodenum oriented superiorly in order to facilitate the enteric anastomosis. Systemic venous drainage was performed to the right common iliac vein or to the vena cava.
Arterial perfusion of the allograft was routinely established from the right common iliac artery. All pancreas allografts were drained enterically using a stapled technique as described elsewhere. 17 For SPK, the pancreas and kidney were typically placed ipsilaterally on the right side as described elsewhere. 18 The immunosuppression protocol consisted of induction with rabbit anti-thymocyte globulin (rATG) (5 mg/kg total dose) along with a single dose of rituximab (150 mg/m 2 ) and maintenance with tacrolimus (target trough 6-8 ng/mL) and sirolimus (target trough 3-6 ng/mL) for SPK and PAK with addition of mycophenolate mofetil 500 mg bid for PTA. Steroids were exclusively used as a premed- Retrospective analysis of data on transplant patients at our center was reviewed and approved by the institutional review board.
Statistical testing was performed on statistical software for the social sciences (IBM SPSS Statistics, IBM Corporation, Armonk, NY, USA).
| RE SULTS
The data were available for all patients in the study and control groups. The minimum follow-up was 6 months. There were 41 recipients of a NIC pancreas transplant. Of these, 13 received an SPK, 14 PAK and 14 PTA. These were matched for age, race, gender, year of transplant and type of transplant with 41 ABO identical pancreas transplants.
The median age of the recipient was 43 years in the study group and 46 years in the control group with 44% males and 56% females in both cohorts. 95% of patients in the control group and 98% in the study group were Caucasian. The 2 groups were comparable for years of diabetes prior to transplant (29 years in the study group and 31 years in the control group) and body mass index (24.9 kg/m 2 in the study group and 24.8 kg/m 2 in the control group). Patients were comparable for immunologic matching with a median of 4HLA antigen mismatch in both groups and median CPRA of 76% in study versus 83% in control group (Table 3) . Three of the 41 in the study group had a zero antigen mismatch. Of the 3, only one had a CPRA >80%.
One patient in the study group had a positive T-cell cross-match with 
(P = .7) The patients with hemolysis did require more PRBC transfusions; however the small sample size limits us from drawing any significant conclusions from the data. None of the patients in the control group had any evidence of hemolysis or a positive Coomb's test during the duration of the study.
The average length of hospital stay after transplant was 8 days in the study group and 6.5 days in the control group (P > .05). The rate of re-admission to hospital within the first 3 months after transplant was 55% and 40% in study and control groups (P > .05). There was 1 case of ACR in the control group while none were seen in the study group (Table 4 ). The median 1 year graft survival by Kaplan-Meier was 100%
in the study group and 88% in the control group (P < .05) (Figure 1 ).
| D ISCUSS I ON
There are variable data on outcomes for liver, kidney, heart, lung, and intestine transplantation using NIC donors. [6] [7] [8] [9] [10] [11] [12] [13] [14] There are, however, no data regarding pancreas transplantation using NIC donors.
Currently the UNOS pancreas transplant committee is investigat- is highest for SPK candidates as compared to kidney alone listed patients for other indications. 19 Patients listed for SPK also have been shown to have higher life years from transplant (LYFT) than kidney recipients. 20 Thus, utilization of pancreas and kidney transplantation for this patient population can be considered as an optimal utilization of a limited resource. 
| CON CLUS ION
ABO compatible and ABO identical pancreas transplants have similar outcomes even when organs are used without a zero antigen mismatch or a CPRA > 80%. AIH may occur after such transplants and is frequently self-limited and can be managed with donor type specific blood transfusion and monitoring.
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